Brain Tumor Pathology最新文献_第8页

Role of proliferative marker index and KBTBD4 mutation in the pathological diagnosis of pineal parenchymal tumors. 增殖标志物指数和KBTBD4突变在松果体实质肿瘤病理诊断中的作用。

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-07-01 Epub Date: 2022-01-09 DOI: 10.1007/s10014-021-00421-2

Eita Uchida, Atsushi Sasaki, Mitsuaki Shirahata, Tomonari Suzuki, Jun-Ichi Adachi, Kazuhiko Mishima, Masanori Yasuda, Takamitsu Fujimaki, Koichi Ichimura, Ryo Nishikawa

{"title":"Role of proliferative marker index and KBTBD4 mutation in the pathological diagnosis of pineal parenchymal tumors.","authors":"Eita Uchida, Atsushi Sasaki, Mitsuaki Shirahata, Tomonari Suzuki, Jun-Ichi Adachi, Kazuhiko Mishima, Masanori Yasuda, Takamitsu Fujimaki, Koichi Ichimura, Ryo Nishikawa","doi":"10.1007/s10014-021-00421-2","DOIUrl":"https://doi.org/10.1007/s10014-021-00421-2","url":null,"abstract":"Pineal parenchymal tumors (PPTs) are clinically rare and a biopsy is often required for a definitive diagnosis. To improve the accuracy of histological assessment of PPTs, we examined the proliferative capacity of PPT cells and investigated DICER1 expression and KBTBD4 mutations. This study included 19 cases of PPTs [3 pineocytomas (PCs), 10 PPTs of intermediate differentiation (PPTID), and 6 pineoblastomas (PBs)]. Immunohistochemistry for Ki-67, PHH3, and DICER1, as well as Sanger sequencing analysis for KBTBD4 mutations, was performed using formalin-fixed paraffin-embedded tissue specimens that were resected during surgery. Tumor cell proliferation was quantified using an image analysis software. For the PHH3 and MIB-1 indices, a significant difference was observed between the PPTIDs and PBs (P < 0.05). Loss of DICER1 was not specific for PB; 0/3 PCs (0.0%), 2/9 PPTIDs (22.2%), and 2/4 PBs (50.0%). KBTBD4 mutations were detected in 1/3 PCs (33.3%), 6/9 PPTIDs (66.7%), and 0/4 PBs (0.0%). Thus, combined application of the proliferative marker index and KBTBD4 mutation analysis may be useful for the differential diagnosis of PPTs. Furthermore, detection of KBTBD4 mutations using Sanger sequencing analysis may support the diagnosis of PPTID.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":"39 3","pages":"130-138"},"PeriodicalIF":3.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39797482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group. 东北和新泻地区老年患者原发性中枢神经系统淋巴瘤预后不良的临床病理危险因素:东北脑肿瘤研究组的多中心、回顾性、队列研究

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-07-01 Epub Date: 2022-03-21 DOI: 10.1007/s10014-022-00427-4

Kenichiro Asano, Yoji Yamashita, Takahiro Ono, Manabu Natsumeda, Takaaki Beppu, Kenichiro Matsuda, Masahiro Ichikawa, Masayuki Kanamori, Masashi Matsuzaka, Akira Kurose, Toshio Fumoto, Kiyoshi Saito, Yukihiko Sonoda, Kuniaki Ogasawara, Yukihiko Fujii, Hiroaki Shimizu, Hiroki Ohkuma, Chifumi Kitanaka, Takamasa Kayama, Teiji Tominaga

{"title":"Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group.","authors":"Kenichiro Asano, Yoji Yamashita, Takahiro Ono, Manabu Natsumeda, Takaaki Beppu, Kenichiro Matsuda, Masahiro Ichikawa, Masayuki Kanamori, Masashi Matsuzaka, Akira Kurose, Toshio Fumoto, Kiyoshi Saito, Yukihiko Sonoda, Kuniaki Ogasawara, Yukihiko Fujii, Hiroaki Shimizu, Hiroki Ohkuma, Chifumi Kitanaka, Takamasa Kayama, Teiji Tominaga","doi":"10.1007/s10014-022-00427-4","DOIUrl":"https://doi.org/10.1007/s10014-022-00427-4","url":null,"abstract":"Clinicopathological risk factors for a poor prognosis were investigated in elderly patients with malignant lymphoma of the central nervous system. A total of 82 pathologically confirmed, CD20-positive, diffuse large B-cell lymphoma patients aged 71 years or older who underwent therapeutic intervention in the Tohoku and Niigata area in Japan were retrospectively reviewed. A univariate analysis was performed by the log-rank test using the Kaplan-Meier method. A Cox proportional hazards model was used for multivariate analysis of risk factors. Of the 82 patients, 39 were male and 43 were female, and their median age at onset was 75 years. At the end of the study, there were 34 relapse-free patients (41.5%), 48 relapse cases (58.5%), median progression-free survival was 18 months, and median overall survival (OS) was 26 months; there were 41 deaths and 41 survivors. Multivariate analysis of median OS showed that Karnofsky Performance Status less than 60% 3 months after treatment (p = 0.022, hazard ratio (HR) = 2.591) was the clinical risk factor, and double expressor lymphoma (p = 0.004, HR = 3.163), expression of programmed death-ligand 1 in tumor infiltrating lymphocytes or tumor-associated macrophages (p < 0.001, HR = 5.455), and Epstein-Barr virus infection (p = 0.031, HR = 5.304) were the pathological risk factors.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":" ","pages":"139-150"},"PeriodicalIF":3.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40310187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas. TERT启动子突变在成人型弥漫性胶质瘤中的预后意义。

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-07-01 Epub Date: 2022-01-31 DOI: 10.1007/s10014-021-00424-z

Hideyuki Arita, Koichi Ichimura

引用次数: 7

Timing of H3K27me3 loss in secondary anaplastic meningiomas. 继发性间变性脑膜瘤中H3K27me3缺失的时间。

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-07-01 Epub Date: 2022-01-06 DOI: 10.1007/s10014-021-00422-1

Serena Ammendola, Valeria Barresi

引用次数: 3

Loss of H3K27me3 in WHO grade 3 meningioma 世界卫生组织3级脑膜瘤H3K27me3缺失

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-06-09 DOI: 10.1007/s10014-022-00436-3

A. Maier, C. B. Brøchner, C. Mirian, J. Haslund-Vinding, J. Bartek, T. Ekström, F. Poulsen, D. Scheie, T. Mathiesen

引用次数: 4

A primary DICER1-sarcoma with KRAS and TP53 mutations in a child with suspected ECCL 疑为ECCL患儿的原发性dicer1肉瘤合并KRAS和TP53突变

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-06-06 DOI: 10.1007/s10014-022-00437-2

Kaiyun Yang, Justin Z. Wang, Nisha Kanwar, A. Villani, O. Ajani, A. Fleming, V. Patil, Y. Mamatjan, Qingxia Wei, D. Malkin, A. Shlien, G. Zadeh, J. Provias

引用次数: 1

Revisiting the definition of glioma recurrence based on a phylogenetic investigation of primary and re-emerging tumor samples: a case report 基于原发性和复发性肿瘤样本的系统发育研究，重新定义胶质瘤复发：一例报告

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-06-06 DOI: 10.1007/s10014-022-00438-1

Toru Umehara, H. Arita, F. Miya, Takamune Achiha, T. Shofuda, E. Yoshioka, D. Kanematsu, Tomoyoshi Nakagawa, M. Kinoshita, Naoki Kagawa, Y. Fujimoto, N. Hashimoto, H. Kiyokawa, Eiichi Morii, T. Tsunoda, Y. Kanemura, H. Kishima

引用次数: 0

Diffusely infiltrating glioma with CREBBP–BCORL1 fusion showing overexpression of not only BCORL1 but BCOR: A case report CREBBP-BCORL1融合的弥漫性浸润性胶质瘤显示BCORL1和BCOR的过度表达：一例报告

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-05-21 DOI: 10.1007/s10014-022-00435-4

Ayako Yamazaki, Y. Arai, K. Fukuoka, Y. Nakano, N. Hama, S. Nakata, K. Makino, J. Kuroda, N. Shinojima, A. Mukasa, Yoshiki Mikami, K. Ichimura, T. Shibata, H. Yokoo, S. Nobusawa

引用次数: 2

Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation 含有BRAF V600E突变的胶质母细胞瘤的临床和放射学表现

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-04-01 DOI: 10.1007/s10014-022-00432-7

Yukitomo Ishi, S. Yamaguchi, Michinari Okamoto, R. Sawaya, S. Endo, Hiroaki Motegi, S. Terasaka, Zen-ichi Tanei, K. Hatanaka, Shinya Tanaka, M. Fujimura

引用次数: 5

A patient with two gliomas with independent oligodendroglioma and glioblastoma biology proved by DNA-methylation profiling: a case report and review of the literature. 2例胶质瘤患者，具有独立的少突胶质细胞瘤和胶质母细胞瘤生物学，dna甲基化分析证实:病例报告和文献复习。

IF 3.3 3区医学

Brain Tumor Pathology Pub Date : 2022-04-01 Epub Date: 2022-01-11 DOI: 10.1007/s10014-021-00423-0

Theo F J Kraus, Christoph Schwartz, Lukas Machegger, Barbara Zellinger, Dorothee Hölzl, Hans U Schlicker, Johannes Pöppe, Barbara Ladisich, Mathias Spendel, Michael Kral, Karl Sotlar

{"title":"A patient with two gliomas with independent oligodendroglioma and glioblastoma biology proved by DNA-methylation profiling: a case report and review of the literature.","authors":"Theo F J Kraus, Christoph Schwartz, Lukas Machegger, Barbara Zellinger, Dorothee Hölzl, Hans U Schlicker, Johannes Pöppe, Barbara Ladisich, Mathias Spendel, Michael Kral, Karl Sotlar","doi":"10.1007/s10014-021-00423-0","DOIUrl":"https://doi.org/10.1007/s10014-021-00423-0","url":null,"abstract":"Here, we report on a patient presenting with two histopathologically distinct gliomas. At the age of 42, the patient underwent initial resection of a right temporal oligodendroglioma IDH mutated 1p/19q co-deleted WHO Grade II followed by adjuvant radiochemotherapy with temozolomide. 15 months after initial diagnosis, the patient showed right hemispheric tumor progression and an additional new left frontal contrast enhancement in the subsequent imaging. A re-resection of the right-sided tumor and resection of the left frontal tumor were conducted. Neuropathological work-up showed recurrence of the right-sided oligodendroglioma with features of an anaplastic oligodendroglioma WHO Grade III, but a glioblastoma WHO grade IV for the left frontal lesion. In depth molecular profiling revealed two independent brain tumors with distinct molecular profiles of anaplastic oligodendroglioma IDH mutated 1p/19q co-deleted WHO Grade III and glioblastoma IDH wildtype WHO grade IV. This unique and rare case of a patient with two independent brain tumors revealed by in-depth molecular work-up and epigenomic profiling emphasizes the importance of integrated work-up of brain tumors including methylome profiling for advanced patient care.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":"39 2","pages":"111-119"},"PeriodicalIF":3.3,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39689454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3